Pandemic Hobbles Drugmakers in Recruiting for New Studies

Published April 28, 2020

A study evaluating a Novartis AG cholesterol drug stopped enlisting patients due to Covid-19, just the latest example of how the pandemic is hampering research across the industry.

Related Stories